Updated on 18 August 2026
高敏量子点体外诊断试剂的应用
CEO at 深圳市金准生物医学工程有限公司
China
About
我们是全球首家研发高灵敏度量子点体外诊断试剂的企业。产品可对各类人体样本中的生物标志物开展检测,同时也可实现毒品、环境样本相关指标的高灵敏检测。
Project Location
- China
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- No
Project Stage
- Operations
Main Project Sector
- Technology
Other Sector(s)
Healthcare
Total Project Value
- 10,000,001 to 25,000,000 USD
Type(s) of Last Financing Round of the project (if Applicable)
- Venture Capital (VC)
Main Service(s) Required
- Financial Services
Financial Services
- Fund Management
- Institutional Investment
Similar opportunities
Project
- No
- No
- Bio-Tech
- Insurance
- Technology
- Securities
- Trust Fund
- E-commerce
- Operations
- Hedge Funds
- Data Centre
- Cloud Solution
- Public Project
- Fund Management
- Private Banking
- Convertible Loan
- Syndicated Loans
- Health Technology
- Health Facilities
- Wealth Management
- Medical Technology
- Financial Services
- Commercial Banking
- Investment Banking
- Enterprise Solutions
- Marketing Technology
- Professional Services
- Environmental Technology
- Institutional Investment
- 5,000,001 to 7,500,000 USD
- Private Equity & Venture Capital
国建 章
董事长 at 深圳市金准生物医学工程有限公司
China
Service
- Oceania
- East Asia
- Consultancy
- Middle East
- Central Asia
- North Africa
- North America
- Mainland China
- Eastern Europe
- Western Europe
- South-East Asia
- Southern Europe
- Northern Europe
- Business Valuation
- Corporate Services
- Financial Advisory
- Sub-Saharan Africa
- Surveying & Valuation
- Professional Services
- Environmental Services
- Advisory & Consultancy
- Architectural Services
- Corporate Intelligence
- Building & Construction
- Financial Due Diligence
- Institutional Investment
- Infrastructure Services
- Construction Engineering
- Port, Terminal & Airport
- Environmental Engineering
- Latin America & Caribbean
- Islamic Finance Institution
- Infrastructure / Utility Investment
- Environmental Management & Consultancy
George Mantas
Business Development Director at AquaBioTech Group
Malta
Project
Human Respiratory Organoid Platform & Applications
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Health Technology
- Medical Technology
- Financial Services
- Open for Negotiation
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- 1,000,001 to 2,500,000 USD
- Government & Public Funding
- Private Equity & Venture Capital
- Investment / Financing Discussion
Roger Zhang
Commercial Director at Centre for Virology, Vaccinology and Therapeutics Limited
China (Hong Kong)